Profiel
Andrew J.
Sonderfan worked as a Director-Toxicology & Product Safety at Biochem Pharma, Inc. from 2000 to 2001.
He then worked as a Senior Director-Toxicology & Safety Pharmacology at Enanta Pharmaceuticals, Inc. After that, he worked as a Vice President-Preclinical Safety Assessment at Synta Pharmaceuticals Corp.
from 2006 to 2011.
Finally, he worked as a Vice President-Toxicology & Early Development at Lysosomal Therapeutics, Inc. Dr. Sonderfan holds a doctorate degree from the University of Kansas and an undergraduate degree from the University of the Sciences in Philadelphia.
Eerdere bekende functies van Andrew J. Sonderfan
| Bedrijven | Functie | Einde |
|---|---|---|
Biochem Pharma, Inc.
 Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Corporate Officer/Principal | 01-01-2001 |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Opleiding van Andrew J. Sonderfan
| University of the Sciences in Philadelphia | Undergraduate Degree |
| University of Kansas | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Health Technology |
Lysosomal Therapeutics, Inc.
Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
